Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics in-house development and manufacturing capabilities in Toulouse, France
Sandoz (OTCQX:SDZNY) has signed a non-binding term sheet with Evotec SE to acquire Just-Evotec Biologics EU SAS for approximately USD 300 million. The acquisition includes the J.POD biologics development and manufacturing facility in Toulouse, France.
The strategic move aims to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The acquisition would enhance Sandoz's in-house biosimilar capabilities through JEB's fully automated and high-throughput technology platform, enabling faster development, smarter scaling, and high-quality manufacturing while controlling costs.
The transaction completion is subject to contract finalization, necessary approvals, and mandatory employee processes in France. Upon completion, JEB employees would be integrated into the Sandoz Group. The investment aligns with Sandoz's existing capital expenditure commitments in Europe.
Sandoz (OTCQX:SDZNY) ha firmato una lettera di intenti non vincolante con Evotec SE per acquisire Just-Evotec Biologics EU SAS per circa 300 milioni di USD. L'acquisizione comprende l'impianto di sviluppo e produzione biologica J.POD situato a Tolosa, Francia.
Questa mossa strategica punta a sfruttare l'opportunit脿 di mercato stimata in 300 miliardi di USD nel settore dei biosimilari nei prossimi dieci anni. L'acquisizione migliorerebbe le capacit脿 interne di Sandoz nei biosimilari grazie alla piattaforma tecnologica completamente automatizzata e ad alto rendimento di JEB, permettendo uno sviluppo pi霉 rapido, una scalabilit脿 intelligente e una produzione di alta qualit脿, mantenendo sotto controllo i costi.
Il completamento della transazione 猫 soggetto alla finalizzazione del contratto, alle necessarie approvazioni e ai processi obbligatori per i dipendenti in Francia. Al termine, i dipendenti di JEB saranno integrati nel Gruppo Sandoz. L'investimento 猫 in linea con gli impegni di spesa in conto capitale gi脿 previsti da Sandoz in Europa.
Sandoz (OTCQX:SDZNY) ha firmado una carta de intenciones no vinculante con Evotec SE para adquirir Just-Evotec Biologics EU SAS por aproximadamente 300 millones de USD. La adquisici贸n incluye la instalaci贸n de desarrollo y fabricaci贸n biol贸gica J.POD en Toulouse, Francia.
Esta estrategia busca aprovechar la oportunidad de mercado proyectada en 300 mil millones de USD en biosimilares durante la pr贸xima d茅cada. La adquisici贸n fortalecer铆a las capacidades internas de biosimilares de Sandoz a trav茅s de la plataforma tecnol贸gica totalmente automatizada y de alto rendimiento de JEB, permitiendo un desarrollo m谩s r谩pido, una escalabilidad inteligente y una fabricaci贸n de alta calidad, controlando los costos.
La finalizaci贸n de la transacci贸n est谩 sujeta a la firma del contrato, las aprobaciones necesarias y los procesos obligatorios para empleados en Francia. Una vez completada, los empleados de JEB se integrar谩n en el Grupo Sandoz. La inversi贸n est谩 alineada con los compromisos de gasto de capital existentes de Sandoz en Europa.
Sandoz (OTCQX:SDZNY)電� Evotec SE鞕� 鞎� 3鞏� 雼煬(USD) 攴滊搿� Just-Evotec Biologics EU SAS毳� 鞚胳垬頃橁赴 鞙勴暅 甑啀霠� 鞐嗠姅 鞏戫暣臧侅劀鞐� 靹滊獏頄堨姷雼堧嫟. 鞚措矆 鞚胳垬鞐愲姅 頂勲瀾鞀� 韴措（歃�鞐� 鞙勳箻頃� J.POD 靸濍頃欖爜 臧滊皽 氚� 鞝滌“ 鞁滌劋鞚� 韽暔霅╇媹雼�.
鞚措矆 鞝勲灥鞝� 臁办箻電� 頄ロ泟 10雲勱皠 3000鞏� 雼煬 攴滊鞚� 氚旍澊鞓れ嫓氚�霟� 鞁滌灔 旮绊殞毳� 頇滌毄頃橁赴 鞙勴暅 瓴冹瀰雼堧嫟. 鞚措矆 鞚胳垬毳� 韱淀暣 JEB鞚� 鞕勳爠 鞛愲彊頇� 氚� 瓿犾矘毽焿 旮办垹 頂岆灚韽检潉 頇滌毄頃橃棳 Sandoz鞚� 鞛愳泊 氚旍澊鞓れ嫓氚�霟� 鞐焿鞚� 臧曧檾霅橃柎 雿� 牍犽ジ 臧滊皽, 鞀る韸疙暅 攴滊 頇曥灔, 瓿犿拡歆� 鞝滌“臧� 臧�電ロ暣歆�氅� 牍勳毄霃� 韱奠牅頃� 靾� 鞛堦矊 霅╇媹雼�.
瓯半灅 鞕勲電� 瓿勳暯 斓滌頇�, 頃勳殧頃� 鞀轨澑 氚� 頂勲瀾鞀� 雮� 頃勳垬 歆侅洂 鞝堨皑毳� 臁瓣贝鞙茧 頃╇媹雼�. 鞕勲 鞁� JEB 歆侅洂霌れ潃 Sandoz 攴鸽９鞐� 韱淀暕霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 韴瀽電� Sandoz臧� 鞙犽熃 雮� 旮办〈鞐� 鞎届啀頃� 鞛愲掣 歆�於� 瓿勴殟瓿茧弰 鞚检箻頃╇媹雼�.
Sandoz (OTCQX:SDZNY) a sign茅 une lettre d'intention non contraignante avec Evotec SE pour acqu茅rir Just-Evotec Biologics EU SAS pour environ 300 millions de dollars US. L'acquisition inclut l'installation de d茅veloppement et de fabrication biologiques J.POD situ茅e 脿 Toulouse, France.
Cette d茅marche strat茅gique vise 脿 tirer parti de l'opportunit茅 de march茅 projet茅e 脿 300 milliards de dollars US dans le secteur des biosimilaires au cours de la prochaine d茅cennie. L'acquisition renforcerait les capacit茅s internes de biosimilaires de Sandoz gr芒ce 脿 la plateforme technologique enti猫rement automatis茅e et 脿 haut d茅bit de JEB, permettant un d茅veloppement plus rapide, une mont茅e en 茅chelle plus intelligente et une fabrication de haute qualit茅 tout en ma卯trisant les co没ts.
La finalisation de la transaction est soumise 脿 la conclusion du contrat, aux approbations n茅cessaires et aux proc茅dures obligatoires pour les employ茅s en France. Une fois termin茅e, les employ茅s de JEB seront int茅gr茅s au groupe Sandoz. Cet investissement s'inscrit dans les engagements de d茅penses en capital d茅j脿 pr茅vus par Sandoz en Europe.
Sandoz (OTCQX:SDZNY) hat eine unverbindliche Absichtserkl盲rung mit Evotec SE unterzeichnet, um Just-Evotec Biologics EU SAS f眉r etwa 300 Millionen USD zu 眉bernehmen. Die 脺bernahme umfasst die J.POD-Biologika-Entwicklungs- und Produktionsanlage in Toulouse, Frankreich.
Dieser strategische Schritt zielt darauf ab, die prognostizierte 300-Milliarden-USD-Biosimilar-Marktchance im n盲chsten Jahrzehnt zu nutzen. Die 脺bernahme w眉rde Sandoz' interne Biosimilar-Kompetenzen durch die vollautomatisierte und hochdurchsatzf盲hige Technologieplattform von JEB verbessern, was eine schnellere Entwicklung, intelligentere Skalierung und hochwertige Fertigung bei gleichzeitiger Kostenkontrolle erm枚glicht.
Der Abschluss der Transaktion steht unter dem Vorbehalt der Vertragsfinalisierung, der erforderlichen Genehmigungen und der obligatorischen Mitarbeiterverfahren in Frankreich. Nach Abschluss w眉rden die Mitarbeiter von JEB in die Sandoz-Gruppe integriert. Die Investition steht im Einklang mit den bestehenden Investitionsverpflichtungen von Sandoz in Europa.
- None.
- Non-binding agreement subject to multiple approval processes
- Significant capital investment of USD 300 million required
- Complex integration process including mandatory employee procedures in France
Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
MEDIA RELEASE
- Proposed transaction would seamlessly align with Sandoz strategic objective of capitalizing on projected USD 300 billion biosimilar market opportunity over next 10 years[1]
- Intended acquisition would reinforce in-house biosimilar development and manufacturing capabilities, while creating additional strategic flexibility
- Sandoz would acquire Just-Evotec Biologics (JEB) activities in Toulouse, France, including proprietary platform for integrated development and advanced continuous manufacturing
Basel, July 30, 2025聽聽 Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed a non-binding term sheet with Evotec SE. This paves the way for Sandoz to potentially acquire
Richard Saynor, CEO of Sandoz, said: 鈥淲e aim to capitalize on the projected USD 300 billion biosimilar market opportunity over the next decade. The intended acquisition is fully in line with our strategy to reinforce in-house biosimilar capabilities, while creating additional strategic flexibility. Following successful completion, the Toulouse site would be used to develop and manufacture Sandoz biosimilars. JEB麓s fully automated and high throughput technology platform will help us move faster, scale smarter, and maintain high quality while keeping costs under control.鈥�
Sandoz and Evotec SE will now work to negotiate details of the contracts and carry out the relevant works-council consultation processes, as well as the mandatory employee bid process in France. Closing the proposed transaction will be subject to finalizing the contracts and obtaining all necessary approvals. Further details of the terms cannot be shared at this stage and will only be disclosed after successful signing of the contracts.
Just-Evotec Biologics has been a key strategic partner for Sandoz since 2023. The proposed acquisition would complement previously announced investments in Sandoz biosimilar manufacturing and development sites. The planned investment would be in line with existing Sandoz capital-expenditure commitments related to Sandoz operations in Europe.
Upon completion of the proposed transaction, JEB employees would transfer with the acquired entity and would become part of the Sandoz Group. JEB brings an advanced and integrated continuous manufacturing platform with automation that enables manufacturing to run continuously end-to-end.
- Based on March 2025 data from IPD Analytics Evaluate Pharma, covering the period 2026鈥�2035.
About Sandoz agreement with JEB
In May 2023, Sandoz and JEB announced a strategic partnership that supports the company鈥檚 portfolio expansion and continued development of its early-stage biosimilar pipeline by providing access to JEB鈥檚 highly-efficient drug substance development platform. The proprietary fully automated and high throughput technology platform allows Sandoz to continue to build out its own integrated drug substance development and manufacturing network.
JEB is also developing an integrated continuous manufacturing platform with automation that enables the manufacturing process to run continuously end-to-end, resulting in enhanced efficiency and cost-effectiveness.
In July 2024, Sandoz secured long-term commercial supply access to JEB鈥檚 biosimilars manufacturing facility in Toulouse, France. In addition, Sandoz secured resource capacity for drug substance development of additional molecules starting in 2025. JEB will also enable the implementation of its design capability and continuous manufacturing technology at Sandoz.
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management鈥檚 views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly revise any forward-looking statements, except as required by law.
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 900 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,300 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world鈥檚 first oral penicillin in 1951, and the world鈥檚 first biosimilar in 2006. In 2024, Sandoz recorded net sales of USD 10.4 billion.
| CONTACTS | |
| Global Media Relations contacts | Investor Relations contacts聽聽 |
| [email protected] | [email protected] |
| Alexis Kalomparis +41 792 790285 | Craig Marks +44 7818 942 383 |
| Joerg E. Allgaeuer +49 171 838 4838 | Rupreet Sandhu +41 79 410 5472 |
Attachment
FAQ
What is the value of Sandoz's acquisition of Just-Evotec Biologics?
What are the strategic benefits of Sandoz (SDZNY) acquiring Just-Evotec Biologics?
What is the status of Sandoz's acquisition of Just-Evotec Biologics as of July 2025?
What will happen to Just-Evotec Biologics employees after the Sandoz acquisition?
What manufacturing capabilities will Sandoz gain from the Just-Evotec Biologics acquisition?
